{
    "Clinical Trial ID": "NCT00398567",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Part 2 - Expanded MTD Cohort",
        "  All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg daily by mouth Herceptin: Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Pathologic diagnosis of breast cancer with current stage IIIB, IIIC or IV not curable by available therapy",
        "  Progression following at least one Herceptin-containing cytotoxic chemotherapy regimen (neoadjuvant, adjuvant, or metastatic setting)",
        "  HER2 positive breast cancer",
        "  At least one measurable target lesion",
        "  Adequate performance status",
        "  Adequate cardiac, kidney, and liver function",
        "  Adequate blood counts",
        "  Willingness of all subjects who are not surgically sterile or post menopausal to use acceptable methods of birth control",
        "Exclusion Criteria:",
        "  More than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease",
        "  Major surgery, chemotherapy, radiotherapy, investigational agents, Herceptin or other cancer therapy within 2 weeks of treatment day 1",
        "  Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2",
        "  Extensive visceral disease",
        "  Active central nervous system metastases",
        "  Pregnant or breast feeding women",
        "  Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom",
        "  Prior exposure to HKI-272 or other HER2 targeted agents (except Herceptin and Tykerb)",
        "  Significant cardiac disease or dysfunction",
        "  History of life-threatening hypersensitivity to Herceptin",
        "  Inability or unwillingness to swallow HKI-272 capsules",
        "  Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  16-week Progression-free Survival (PFS) Rate",
        "  16-week progression-free survival (PFS) rate for subjects with advanced breast cancer who receive neratinib at the maximum tolerated dose (MTD) in combination with trastuzumab, evaluable population.",
        "  Time frame: From first dose date to progression status (PD or death) at 16-week",
        "Results 1: ",
        "  Arm/Group Title: Part 2 - Expanded MTD Cohort",
        "  Arm/Group Description: All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg daily by mouth Herceptin: Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of population  44.8        (25.9 to 62.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/4 (25.00%)",
        "  Vertigo 0/4 (0.00%)",
        "  Abdominal adhesions 0/4 (0.00%)",
        "  Abdominal distension 0/4 (0.00%)",
        "  Abdominal pain 0/4 (0.00%)",
        "  Diarrhoea 0/4 (0.00%)",
        "  Nausea 0/4 (0.00%)",
        "  Vomiting 0/4 (0.00%)",
        "  Disease progression 0/4 (0.00%)",
        "  Influenza 0/4 (0.00%)",
        "  Nasopharyngitis 0/4 (0.00%)",
        "  Lumbar vertebral fracture 0/4 (0.00%)",
        "  Hyponatraemia 0/4 (0.00%)",
        "  Ataxia 0/4 (0.00%)"
    ]
}